1887

Abstract

5-Fluorouracil (5-FU), a commonly used chemotherapeutic agent, often causes oral mucositis, an inflammation and ulceration of the oral mucosa. Micro-organisms in the oral cavity are thought to play an important role in the aggravation and severity of mucositis, but the mechanisms behind this remain unclear. Although 5-FU has been shown to elicit antibacterial effects at high concentrations (>100 µM), its antibacterial effect at physiologically relevant concentrations in the oral cavity is unknown. This study reports the effect of different concentrations of 5-FU (range 0.1–50 µM) on the growth and viability of bacterial monocultures that are present in the oral cavity and the possible role in the activity of dihydropyrimidine dehydrogenase (DPD), an enzyme involved in 5-FU resistance. Our data showed a differential sensitivity among the tested oral species towards physiological concentrations of 5-FU. , ,,, and appeared to be highly resistant to all tested concentrations. In contrast, , ,, and showed a significant reduction in growth and viability starting from very low concentrations (0.2–3.1 µM). We can also provide evidence that DPD is not involved in the 5-FU resistance of the selected species. The observed variability in response to physiological 5-FU concentrations may explain why certain microbiota lead to a community dysbiosis and/or an overgrowth of certain resistant micro-organisms in the oral cavity following cancer treatment.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000292
2016-08-01
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/8/775.html?itemId=/content/journal/jmm/10.1099/jmm.0.000292&mimeType=html&fmt=ahah

References

  1. Aziz Q., Doré J., Emmanuel A., Guarner F., Quigley E. M.. 2013; Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil25:4–15 [CrossRef][PubMed]
    [Google Scholar]
  2. Beck A., Etienne M. C., Chéradame S., Fischel J. L., Formento P., Renée N., Milano G.. 1994; A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer30:1517–1522 [CrossRef]
    [Google Scholar]
  3. Berney M., Hammes F., Bosshard F., Weilenmann H. U., Egli T.. 2007; Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl Environ Microbiol73:3283–3290 [CrossRef][PubMed]
    [Google Scholar]
  4. Bocci G., Danesi R., Di Paolo A. D., Innocenti F., Allegrini G., Falcone A., Melosi A., Battistoni M., Barsanti G. et al. 2000; Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res6:3032–3037[PubMed]
    [Google Scholar]
  5. Bodet C. A., Jorgensen J. H., Drutz D. J.. 1985; Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother28:437–439 [CrossRef][PubMed]
    [Google Scholar]
  6. Carnel S. B., Blakeslee D. B., Oswald S. G., Barnes M.. 1990; Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg102:326–330 [CrossRef][PubMed]
    [Google Scholar]
  7. Casale F., Canaparo R., Serpe L., Muntoni E., Pepa C. D., Costa M., Mairone L., Zara G. P., Fornari G., Eandi M.. 2004; Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res50:173–179 [CrossRef][PubMed]
    [Google Scholar]
  8. Clark J. L., Berger S. H., Mittelman A., Berger F. G.. 1987; Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep71:261–265[PubMed]
    [Google Scholar]
  9. Dewhirst F. E., Chen T., Izard J., Paster B. J., Tanner A. C., Yu W. H., Lakshmanan A., Wade W. G.. 2010; The human oral microbiome. J Bacteriol192:5002–5017 [CrossRef][PubMed]
    [Google Scholar]
  10. Diasio R. B., Beavers T. L., Carpenter J. T.. 1988; Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest81:47–51 [CrossRef][PubMed]
    [Google Scholar]
  11. Diasio R. B., Harris B. E.. 1989; Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet16:215–237 [CrossRef][PubMed]
    [Google Scholar]
  12. Goldschmidt M. C., Bodey G. P.. 1972; Effect of chemotherapeutic agents upon microorganisms isolated from cancer patients. Antimicrob Agents Chemothera1:348–353 [CrossRef]
    [Google Scholar]
  13. Grem J. L.. 2000; 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs18:299–313[PubMed][CrossRef]
    [Google Scholar]
  14. Harris B. E., Carpenter J. T., Diasio R. B.. 1991; Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer68:499–501 [CrossRef][PubMed]
    [Google Scholar]
  15. Hidese R., Mihara H., Kurihara T., Esaki N.. 2011; Escherichia coli dihydropyrimidine dehydrogenase is a novel NAD-dependent heterotetramer essential for the production of 5,6-dihydrouracil. J Bacteriol193:989–993 [CrossRef][PubMed]
    [Google Scholar]
  16. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L.. 1995; Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res55:1407–1412[PubMed]
    [Google Scholar]
  17. Joulia J. M., Pinguet F., Ychou M., Duffour J., Astre C., Bressolle F.. 1999; Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer35:296–301 [CrossRef][PubMed]
    [Google Scholar]
  18. Kahm M., Hasenbrink G., Lichtenberg-Fraté H., Ludwig J., Kschischo M.. 2010; Grofit: fitting biological growth curves with R. J Stat Softw33:1–21 [CrossRef]
    [Google Scholar]
  19. Kim S., West T. P.. 1991; Pyrimidine catabolism in Pseudomonas aeruginosa . FEMS Microbiol Lett77:175–179 [CrossRef]
    [Google Scholar]
  20. Kim S., Park D. H., Shim J.. 2008; Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans . Mol Cells26:344–349[PubMed]
    [Google Scholar]
  21. Kosovec J. E., Egorin M. J., Gjurich S., Beumer J. H.. 2008; Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom22:224–230 [CrossRef][PubMed]
    [Google Scholar]
  22. Longley D. B., Harkin D. P., Johnston P. G.. 2003; 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer3:330–338 [CrossRef][PubMed]
    [Google Scholar]
  23. Lucas V. S., Beighton D., Roberts G. J., Challacombe S. J.. 1997; Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect35:135–141 [CrossRef][PubMed]
    [Google Scholar]
  24. Marsh P., Martin M. V.. 1999; Oral Microbiology London: Chapman & Hall;
    [Google Scholar]
  25. Mechergui A., Achour W., Baaboura R., Ouertani H., Lakhal A., Torjemane L., Othman T. B., Hassen A. B., Ben Othman T., Ben Hassen A.. 2014; Case report of bacteremia due to Neisseria mucosa . APMIS122:359–361 [CrossRef][PubMed]
    [Google Scholar]
  26. Napeñas J. J., Brennan M. T., Coleman S., Kent M. L., Noll J., Frenette G., Nussbaum M. L., Mougeot J. -L., Paster B. J. et al. 2010; Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod109:554–560 [CrossRef]
    [Google Scholar]
  27. Omura K.. 2003; Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol8:132–138 [CrossRef][PubMed]
    [Google Scholar]
  28. Panghal M., Kaushal V., Kadayan S., Yadav J. P.. 2012; Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health12:12 [CrossRef]
    [Google Scholar]
  29. Peterson D. E., Sonis S. T.. 1982; Oral complications of cancer chemotherapy: present status and future studies. Cancer Treat Rep66:1251–1256[PubMed]
    [Google Scholar]
  30. Saif M. W., Choma A., Salamone S. J., Chu E.. 2009; Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst101:1543–1552 [CrossRef][PubMed]
    [Google Scholar]
  31. Salonga D., Danenberg K. D., Johnson M., Metzger R., Groshen S., Tsao-Wei D. D., Lenz H. J., Leichman C. G., Leichman L. et al. 2000; Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res6:1322–1327[PubMed]
    [Google Scholar]
  32. Stringer A. M., Gibson R. J., Logan R. M., Bowen J. M., Yeoh A. S., Hamilton J., Keefe D. M.. 2009; Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med234:430–441 [CrossRef][PubMed]
    [Google Scholar]
  33. Stringer A. M., Logan R. M.. 2015; The role of oral flora in the development of chemotherapy-induced oral mucositis. J Oral Pathol Med44:81–87 [CrossRef][PubMed]
    [Google Scholar]
  34. Takahata M., Yamashiro Y., Yotsuji A., Fukuoka Y., Yasuda T., Saikawa I., Ueda Y.. 1986; Enhancement of 5-fluorouracil uptake into the bacterial cell by piperacillin. J Antibiot39:1167–1171 [CrossRef][PubMed]
    [Google Scholar]
  35. Takechi T., Uchida J., Fujioka A., Fukushima M.. 1997; Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol11:1041–1044 [CrossRef][PubMed]
    [Google Scholar]
  36. Takimoto C. H., Lu Z. H., Zhang R., Liang M. D., Larson L. V., Cantilena L. R., Grem J. L., Allegra C. J., Diasio R. B., Chu E.. 1996; Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res2:477–481[PubMed]
    [Google Scholar]
  37. Takimoto C. H., Yee L. K., Venzon D. J., Schuler B., Grollman F., Chabuk C., Hamilton J. M., Chen A. P., Allegra C. J., Grem J. L, Green J. L.. 1999; High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res5:1347–1352[PubMed]
    [Google Scholar]
  38. Ueda Y., Saito A., Fukuoka Y., Yamashiro Y., Ikeda Y., Taki H., Yasuda T., Saikawa I.. 1983; Interactions of beta-lactam antibiotics and antineoplastic agents. Antimicrob Agents Chemother23:374–378 [CrossRef][PubMed]
    [Google Scholar]
  39. Van Nevel S., Koetzsch S., Weilenmann H. U., Boon N., Hammes F.. 2013; Routine bacterial analysis with automated flow cytometry. J Microbiol Methods94:73–76 [CrossRef][PubMed]
    [Google Scholar]
  40. Vanhoecke B., De Ryck T., Stringer A., Van de Wiele T., Keefe D.. 2015; Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis21:17–30 [CrossRef][PubMed]
    [Google Scholar]
  41. Villa A., Sonis S. T.. 2015; Mucositis: pathobiology and management. Curr Opin Oncol27:159–164 [CrossRef][PubMed]
    [Google Scholar]
  42. Von Bültzingslöwen I., Adlerberth I., Wold A. E., Dahlén G., Jontell M.. 2003; Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol18:278–284 [CrossRef][PubMed]
    [Google Scholar]
  43. Wescombe P. A., Hale J. D., Heng N. C., Tagg J. R.. 2012; Developing oral probiotics from Streptococcus salivarius . Future Microbiol7:1355–1371 [CrossRef][PubMed]
    [Google Scholar]
  44. West T. P.. 1998; Isolation and characterization of an Escherichia coli B mutant strain defective in uracil catabolism. Can J Microbiol44:1106–1109 [CrossRef][PubMed]
    [Google Scholar]
  45. Wright D. N., Matsen J. M.. 1980; Bioassay of antibiotics in body fluids from patients receiving cancer chemotherapeutic agents. Antimicrob Agents Chemother17:417–422 [CrossRef][PubMed]
    [Google Scholar]
  46. Zijnge V., van Leeuwen M. B., Degener J. E., Abbas F., Thurnheer T., Gmür R., Harmsen H. J., M. Harmsen H. J.. 2010; Oral biofilm architecture on natural teeth. PLoS One5:e9321 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000292
Loading
/content/journal/jmm/10.1099/jmm.0.000292
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error